Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review

IMPORTANCE: Immunotherapy (anti–programmed death ligand 1 antibodies) is associated with improved survival rates in advanced kidney cell carcinoma (KCC) after progression on first-line tyrosine kinase inhibitor (TKI) treatment. It is unknown whether and to what degree patients in the control arm rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharp, John, Khaki, Ali Raza, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477261/
https://www.ncbi.nlm.nih.gov/pubmed/34570209
http://dx.doi.org/10.1001/jamanetworkopen.2021.24728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477261/
https://www.ncbi.nlm.nih.gov/pubmed/34570209
http://dx.doi.org/10.1001/jamanetworkopen.2021.24728

Ejemplares similares